Overview

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of KRP203 in clinically active subacute cutaneous lupus erythematosus patients, who have demonstrated inadequate response to standard treatment, such as antimalarials.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals